Alkermes plc

ALKSUnited States

56 filed reports · 570 financial concepts · 12 earnings calls · 2 media appearances

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$1.48B

FY2025 · to Dec 31, 2025

down −5.2% vs $1.56B

10-K

Net income

$242M

FY2025 · to Dec 31, 2025

down −34.2% vs $367M

10-K

Latest quarter

Revenue

$480M

Q3 FY2026 · to Sep 30, 2026

up +21.8% vs $394M

10-Q

Net income

-$66.5M

Q1 FY2026 · to Mar 31, 2026

a year earlier: $22.5M

10-Q

Filed reports

56 reports · Mar 2017 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 9 operating metrics, 124 guidance figures, 118 earnings-release figures, 98 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR315,829Mar 2017 to Sep 2026
Current · 8-KSEC EDGAR12221Sep 2017 to Sep 2026
Annual · 10-KSEC EDGAR104,300Dec 2017 to Dec 2025
Annual · 10-K/ASEC EDGAR33Dec 2020 to Dec 2022

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q38-K2026-09-302026-11-0395Open
FY2026 Q310-Q2026-09-302026-11-03472Open
FY2026 Q210-Q2026-06-302026-07-28277Open
FY2026 Q110-Q2026-03-312026-05-05275Open
FY2026 Q110-Q2026-03-312026-05-053Open
FY202510-K2025-12-312026-02-2511Open
FY202510-K2025-12-312026-02-25904Open
FY2025 Q310-Q2025-09-302025-10-28229Open
FY2025 Q210-Q2025-06-302025-07-29188Open
FY2025 Q110-Q2025-03-312025-05-01192Open
FY202410-K2024-12-312025-02-12448Open
FY2024 Q310-Q2024-09-302024-10-24202Open

Financial data

570 concepts · 10,353 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial499 concepts · 9,525 facts · Dec 2015 to Sep 2026

  • Amortized Cost80 · Dec 2016 to Mar 2024
  • Gross Unrealized Losses, Less than One Year80 · Dec 2016 to Mar 2024
  • Gross Unrealized Gains65 · Dec 2016 to Mar 2024
  • Cash and cash equivalents at carrying value55 · Dec 2015 to Sep 2026
  • Allocated share based compensation expense54 · Dec 2015 to Sep 2026
  • Comprehensive income net of tax54 · Dec 2015 to Sep 2026
  • Costs and expenses54 · Dec 2015 to Sep 2026
  • Deferred income tax expense benefit54 · Dec 2015 to Sep 2026
  • Depreciation depletion and amortization54 · Dec 2015 to Sep 2026
  • Income tax expense benefit54 · Dec 2015 to Sep 2026
  • Increase decrease in accounts payable and accrued liabilities54 · Dec 2015 to Sep 2026
  • Increase decrease in inventories54 · Dec 2015 to Sep 2026
  • Increase decrease in other operating liabilities54 · Dec 2015 to Sep 2026
  • Increase decrease in receivables54 · Dec 2015 to Sep 2026
  • Investment income interest54 · Dec 2015 to Sep 2026
  • Noncash or part noncash acquisition value of liabilities assumed154 · Dec 2015 to Sep 2026
  • Nonoperating income expense54 · Dec 2015 to Sep 2026
  • Operating income loss54 · Dec 2015 to Sep 2026
  • Other comprehensive income unrealized holding gain loss on securities arising during period net of tax54 · Dec 2015 to Sep 2026
  • Other comprehensive income unrealized holding gain loss on securities arising during period tax54 · Dec 2015 to Sep 2026
  • Other nonoperating income expense54 · Dec 2015 to Sep 2026
  • Payments related to tax withholding for share based compensation54 · Dec 2015 to Sep 2026
  • Payments to acquire marketable securities54 · Dec 2015 to Sep 2026
  • Payments to acquire property plant and equipment54 · Dec 2015 to Sep 2026

Product7 concepts · 438 facts · Dec 2016 to Sep 2026

  • Revenue398 · Dec 2016 to Sep 2026
  • Accounts Payable17 · Dec 2022 to Mar 2026
  • Biogen7 · Dec 2019 to Dec 2025
  • Revenue (excluding assessed tax)7 · Nov 2017 to Sep 2019
  • VIVITROL6 · Jun 2020 to Dec 2020
  • Cost of goods and services sold (US GAAP)2 · Mar 2017 to Mar 2018
  • Contract with customer liability revenue recognized1 · Sep 2018

Guidance7 concepts · 126 facts · Oct 2017 to Feb 2021

  • Net Income Guidance22 · Oct 2017 to Feb 2021
  • Revenue Guidance22 · Oct 2017 to Feb 2021
  • Capital Expenditures Guidance20 · Oct 2017 to Feb 2021
  • EPS (Diluted) Guidance20 · Oct 2017 to Feb 2021
  • Net Income Guidance (Adjusted (non-GAAP))20 · Oct 2017 to Feb 2021
  • EPS (Diluted) Guidance (Adjusted (non-GAAP))16 · Feb 2018 to Feb 2021
  • EPS (Diluted) Guidance (basic; Adjusted (non-GAAP))6 · Oct 2018 to Oct 2019

Geography12 concepts · 121 facts · Dec 2015 to Mar 2026

  • Revenue40 · Dec 2015 to Dec 2025
  • Income loss from continuing operations before income taxes minority interest and income loss from equity method investments24 · Dec 2015 to Dec 2020
  • Total Current Assets18 · Dec 2016 to Dec 2022
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest16 · Dec 2019 to Dec 2025
  • Cash and Equivalents6 · Dec 2023 to Dec 2025
  • Property, Plant & Equipment, Net6 · Dec 2023 to Dec 2025
  • Deferred income tax expense benefit4 · Dec 2016 to Dec 2019
  • Deferred foreign income tax expense benefit2 · Dec 2018 to Dec 2019
  • Pretax Income2 · Dec 2021
  • Current foreign tax expense benefit1 · Dec 2021
  • EU1 · Dec 2022
  • Statutory tax rate1 · Mar 2026

KPI26 concepts · 105 facts · Sep 2025 to Sep 2026

  • Average Selling Price per Unit YoY Change12 · Sep 2025 to Jun 2026
  • Research and development9 · Sep 2025 to Sep 2026
  • Cost of goods manufactured and sold8 · Sep 2025 to Sep 2026
  • Selling, general and administrative7 · Sep 2025 to Sep 2026
  • Interest income6 · Sep 2025 to Sep 2026
  • Amortization of acquired intangible assets5 · Sep 2025 to Sep 2026
  • Depreciation expense4 · Sep 2025 to Sep 2026
  • EBITDA4 · Sep 2025 to Sep 2026
  • Income Tax Provision4 · Sep 2025 to Sep 2026
  • (Loss) Income Before Income Taxes4 · Sep 2025 to Sep 2026
  • Manufacturing and royalty revenues4 · Sep 2025 to Sep 2026
  • Share-based compensation4 · Sep 2025 to Sep 2026
  • Total Expenses4 · Sep 2025 to Sep 2026
  • Total Proprietary Net Sales4 · Sep 2025 to Sep 2026
  • Change in the fair value of contingent consideration3 · Sep 2026
  • Interest expense3 · Sep 2026
  • Cash, cash equivalents and total investments2 · Dec 2025 to Sep 2026
  • Costs related to the acquisition of Avadel2 · Sep 2026
  • (Loss) Earnings Per Share - Basic2 · Sep 2025 to Sep 2026
  • (Loss) Earnings Per Share - Diluted2 · Sep 2025 to Sep 2026
  • Net (Loss) Income — GAAP2 · Sep 2025 to Sep 2026
  • Operating Income2 · Sep 2025 to Sep 2026
  • Other current liabilities2 · Dec 2025 to Sep 2026
  • Other (expense) income, net2 · Sep 2025 to Sep 2026

Segment19 concepts · 38 facts · Sep 2025 to Sep 2026

  • Alixorexton2 · Sep 2025 to Sep 2026
  • Cost of goods and services sold (US GAAP)2 · Sep 2025 to Sep 2026
  • Depreciation2 · Sep 2025 to Sep 2026
  • Employee-related2 · Sep 2025 to Sep 2026
  • General and administrative expense (US GAAP)2 · Sep 2025 to Sep 2026
  • LUMRYZ2 · Sep 2025 to Sep 2026
  • LYBALVI2 · Sep 2025 to Sep 2026
  • Net income loss2 · Sep 2025 to Sep 2026
  • Occupancy2 · Sep 2025 to Sep 2026
  • Other external R&D expenses2 · Sep 2025 to Sep 2026
  • Other internal R&D expenses2 · Sep 2025 to Sep 2026
  • Other orexin programs2 · Sep 2025 to Sep 2026
  • Research and development expense2 · Sep 2025 to Sep 2026
  • Revenue2 · Sep 2025 to Sep 2026
  • Segment reporting other item amount2 · Sep 2025 to Sep 2026
  • Selling and marketing expense (US GAAP)2 · Sep 2025 to Sep 2026
  • Selling general and administrative expense2 · Sep 2025 to Sep 2026
  • Total external R&D expenses2 · Sep 2025 to Sep 2026
  • Total internal R&D expenses2 · Sep 2025 to Sep 2026

Segments

597 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or servicesrt:ProductOrServiceAxis15 members · 416 facts

  • Vivitrol52 · Dec 2016 to Sep 2026
  • Manufactured Product And Royalty49 · Dec 2016 to Sep 2026
  • Product49 · Dec 2016 to Sep 2026
  • Research And Development45 · Dec 2016 to Sep 2025
  • Manufacturing Revenue42 · Dec 2017 to Sep 2026
  • Royalty42 · Dec 2017 to Sep 2026
  • Aristada And Aristada Initio35 · Dec 2018 to Sep 2026
  • License24 · Dec 2017 to Dec 2022
  • LYBALVI24 · Dec 2021 to Sep 2026
  • Aristada17 · Dec 2016 to Dec 2020
  • State usmedicaid rebates10 · Dec 2023 to Mar 2026
  • Aristada Or Aristada Initio10 · Dec 2017 to Sep 2020
  • State medicaid rebates7 · Dec 2022 to Dec 2025
  • Vumerity7 · Dec 2019 to Dec 2025
  • LUMRYZ3 · Mar 2026 to Sep 2026

Statement geographicalsrt:StatementGeographicalAxis6 members · 83 facts

  • IE29 · Dec 2016 to Mar 2026
  • US22 · Dec 2016 to Dec 2025
  • Foreign Country Excluding Specified Country18 · Dec 2016 to Dec 2025
  • Ie6 · Dec 2023 to Dec 2025
  • Us6 · Dec 2023 to Dec 2025
  • European Union2 · Dec 2022

Statement business segments1 member · 38 facts

  • Single Reporting38 · Sep 2025 to Sep 2026

Statement geographicalus-gaap:StatementGeographicalAxis6 members · 38 facts

  • Ie8 · Dec 2016 to Dec 2022
  • Us8 · Dec 2016 to Dec 2022
  • Foreign Country Excluding Specified Country6 · Dec 2015 to Dec 2017
  • IE6 · Dec 2015 to Dec 2017
  • US6 · Dec 2015 to Dec 2017
  • Foreign country excluding specified country4 · Dec 2016 to Dec 2019

Product or serviceus-gaap:ProductOrServiceAxis12 members · 22 facts

  • Research and development4 · Nov 2017 to Sep 2019
  • Manufactured Product And Royalty4 · Mar 2017 to Mar 2018
  • Aristada2 · Mar 2017 to Mar 2018
  • Product2 · Mar 2017 to Mar 2018
  • Research And Development2 · Mar 2017 to Mar 2018
  • Vivitrol2 · Mar 2017 to Mar 2018
  • Clinical supply1 · Nov 2017
  • Research and development revenue1 · Nov 2017
  • Clinical Supply1 · Mar 2018
  • License1 · Mar 2018
  • Research And Development Revenue1 · Mar 2018
  • License1 · Nov 2017

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary126 claims from 12 reports · Sep 2024 to Sep 2026
  • Management discussion (MD&A) commentary197 claims from 9 reports · Sep 2024 to Sep 2026
  • Risk-factor changes128 claims from 8 reports · Dec 2018 to Dec 2025
  • Risk factors363 risks from 9 annual reports · 2017 to 2025

Earnings calls

12 calls · Feb 2024 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-03
  • FY2026 Q22026-07-28
  • FY2026 Q12026-05-05
  • FY2025 Q42026-02-25
  • FY2025 Q32025-10-28
  • FY2025 Q22025-07-29
  • FY2025 Q12025-05-01
  • FY2024 Q42025-02-12
  • FY2024 Q32024-10-24
  • FY2024 Q22024-07-24
  • FY2024 Q12024-05-01
  • FY2023 Q42024-02-15

Executive media

2 appearances

Podcasts, interviews and conference appearances by the company's executives, with their claims.

  • Other appearances2 · Jul 2023 to Jan 2025

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Alkermes plc (ALKS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 21, 2026) and refreshed every few hours.

Alkermes plc (ALKS): FY2025 revenue $1.48B · FactIQ